This study involves a medicine called NKT2152 that may help people with advanced clear cell renal cell carcinoma (ccRCC), a type of kidney cancer. The study is divided into two parts:
Phase 1 aims to find the best dose of NKT2152 that patients can handle. This part is for adults who have tried other treatments that did not work. The medicine is taken by mouth every day.
Phase 2 will check if the medicine works well and is safe for the patients. Participants will be randomly given one of two doses to see which works better.
- This study may require multiple visits and tests to check your health and progress.
- Participants might experience side effects, as the treatment is still being tested.
- Compensation is not mentioned, so discuss this with the study team.
To join, you must be at least 18 years old, able to walk a certain distance, and have a life expectancy of at least 3 months. You should not have any serious heart or lung issues, other cancers, or active infections. If you're interested, ensure you understand the requirements and discuss them with the study team.